APVO Aptevo Therapeutics Inc.

Nasdaq aptevotherapeutics.com


$ 1.55 $ -0.08 (-4.91 %)    

Wednesday, 15-Oct-2025 13:16:24 EDT
QQQ $ 596.80 $ -7.22 (-1.2 %)
DIA $ 460.91 $ -3.73 (-0.8 %)
SPY $ 659.92 $ -6.86 (-1.03 %)
TLT $ 90.67 $ -0.29 (-0.32 %)
GLD $ 385.59 $ -0.37 (-0.1 %)
$ 1.63
$ 1.61
$ 1.54 x 3,361
$ 1.56 x 3,223
$ 1.55 - $ 1.66
$ 1.32 - $ 381.10
1,544,367
na
5.36M
$ 2.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-18-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-13-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-25-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Inte...

 aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results

APVO shares rose 46.10% to $2.06 after promising clinical results, but the stock has dropped 98.84% over the past year.

 steven-cohen-reports-91-passive-stake-in-aptevo-therapeutics--as-of-september-16

-SEC Filing

 aptevos-mipletamig-achieves-100-remission-with-favorable-safety-in-phase-1b2-aml-trial-cohort-4-now-open-for-enrollment

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable s...

 aptevo-expands-anti-cancer-pipeline-with-patents-for-apvo452-apvo451-acute-myeloid-leukemia-candidate-mipletamig-shows-strong-clinical-validation

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor canc...

 aptevo-unveils-apvo442-precision-cd3-bispecific-for-prostate-cancer-advancing-solid-tumor-strategy-with-cris-7-platform

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for preci...

 aptevo-therapeutics-q2-eps-840-beats-8320-estimate

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(8.40) per share which beat the analyst consensus estimate of $...

 aptevo-therapeutics-files-for-offer-and-resale-of-up-to-83m-shares-of-common-stock-by-selling-stockholder

-SEC Filing

 benzinga-bulls-and-bears-circle-sunrun-jetblue--and-mideast-has-markets-nervous

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION